title: Outcome of an optional HCV screening program for blood transfusion recipients in Ireland.
abstract: BACKGROUND
  An optional (general) HCV testing program for blood and blood component recipients before the introduction of routine donor anti-HCV screening (October 1991) was launched in Ireland in 1995 to complement the targeted lookback program in progress at that time and to identify transfusion-transmitted hepatitis C.
  
  
  METHODS
  The public were informed of the opportunity to avail of screening by widespread media coverage. Screening was by an initial ELISA (Abbott 3.0, Abbott Laboratories) at the transfusion center laboratories. Reactive samples were referred to a virus reference laboratory where two additional ELISAs (Ortho 3.0, Ortho Clinical Diagnostics; and Murex 3.0, Murex) were performed. Confirmation of ELISA-positive samples was by a RIBA (RIBA 3.0, Chiron Corp.). All patients found to be anti-HCV- seropositive were tested for HCV RNA by PCR and were referred to a hepatologist.
  
  
  RESULTS
  A total of 14,917 persons have been tested for hepatitis C in this program to date (85% women). Sixty-one people were confirmed positive for HCV by RIBA 3.0 (0.4%). Excluding persons with other risk factors (n = 15), the HCV positivity rate for blood component transfusion recipients (n = 46) was 0.3 percent. Of the 46 confirmed hepatitis C-positive blood component transfusion recipients, 32 were women (70%), 24 of whom received transfusion for obstetric or gynecologic indications (75%). Thirty-eight of 46 (83%) anti-HCV seropositive transfusion recipients tested had detectable HCV RNA by PCR.
  
  
  CONCLUSIONS
  This program identified 46 transfusion recipients and 10 coagulation factor concentrate recipients, all of whom were previously unaware of their infection. The majority of HCV-positive transfusion recipients identified were women. This may reflect that women are longer living survivors of transfusion therapy or alternatively, in our experience, that Irish women perceive themselves at greater risk of hepatitis C because of the well-publicized association of this virus with recipients (women) of Irish RhIG.
authors.affiliation: Irish Blood Transfusion Service, National Blood Center, Dublin, Ireland. AMDavoren@bcsew.edu
authors.forename: Anne
authors.initials: A
authors.lastname: Davoren
authors.forename: Annette D
authors.initials: AD
authors.lastname: Dillon
authors.forename: Joan P
authors.initials: JP
authors.lastname: Power
authors.forename: Joe
authors.initials: J
authors.lastname: Donnellan
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Quinn
authors.forename: Joe W
authors.initials: JW
authors.lastname: Willis
authors.forename: Emer M
authors.initials: EM
authors.lastname: Lawlor
authors.forename: Joan M
authors.initials: JM
authors.lastname: O'Riordan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D016913:Blood Component Transfusion / Q000009:adverse effects; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D018562:Disease Transmission, Infectious; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission*; D018937:Hepatitis C Antibodies / Q000097:blood; D006801:Humans; D015151:Immunoblotting; D007223:Infant; D007494:Ireland / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000706:statistics & numerical data; D008875:Middle Aged; D015995:Prevalence; D015397:Program Evaluation; D012367:RNA, Viral / Q000097:blood; D006435:Renal Dialysis / Q000009:adverse effects; D012307:Risk Factors; D016036:Seroepidemiologic Studies; D015819:Substance Abuse, Intravenous / Q000150:complications; D065227:Transfusion Reaction; D014766:Viremia / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000635:transmission
chemical_list: D018937:Hepatitis C Antibodies; D012367:RNA, Viral